{"id":"dbv712","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site reactions (erythema, pruritus)"},{"rate":null,"effect":"Eczema exacerbation"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DBV712 uses DBV Technologies' proprietary Viaskin patch technology to apply allergen extract to intact skin, targeting skin-associated lymphoid tissue to promote regulatory T cell responses and immune tolerance. This epicutaneous route of allergen delivery is designed to reprogram the immune system to reduce allergic responses without systemic absorption.","oneSentence":"DBV712 is an epicutaneous immunotherapy (EPIT) that delivers allergen to the immune system through the skin to induce immune tolerance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:47.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peanut allergy (oral immunotherapy tolerance induction)"}]},"trialDetails":[{"nctId":"NCT07003919","phase":"PHASE3","title":"Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)","status":"RECRUITING","sponsor":"DBV Technologies","startDate":"2025-06-24","conditions":"Allergy, Peanut Allergy","enrollment":480},{"nctId":"NCT05741476","phase":"PHASE3","title":"Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"DBV Technologies","startDate":"2023-02-21","conditions":"Allergy, Peanut","enrollment":600},{"nctId":"NCT05424731","phase":"","title":"Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children","status":"AVAILABLE","sponsor":"DBV Technologies","startDate":"","conditions":"Peanut Allergy","enrollment":""},{"nctId":"NCT02636699","phase":"PHASE3","title":"Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2015-12","conditions":"Peanut Allergy","enrollment":500},{"nctId":"NCT03859700","phase":"PHASE3","title":"Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2018-12-06","conditions":"Peanut Allergy","enrollment":304},{"nctId":"NCT04371627","phase":"","title":"Viaskin® Peanut (DBV712) Expanded Access Protocol","status":"NO_LONGER_AVAILABLE","sponsor":"DBV Technologies","startDate":"","conditions":"Peanut Allergy","enrollment":""},{"nctId":"NCT03013517","phase":"PHASE3","title":"Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children","status":"UNKNOWN","sponsor":"DBV Technologies","startDate":"2017-01-23","conditions":"Peanut Allergy","enrollment":300},{"nctId":"NCT03352726","phase":"PHASE1","title":"A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2017-11-24","conditions":"Peanut Allergy","enrollment":27},{"nctId":"NCT01904604","phase":"PHASE2","title":"Peanut Epicutaneous Phase II Immunotherapy Clinical Trial","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09","conditions":"Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity","enrollment":75},{"nctId":"NCT01197053","phase":"PHASE2","title":"Epicutaneous Immunotherapy in Peanut Allergy in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-08","conditions":"Peanut Allergy","enrollment":60},{"nctId":"NCT01170286","phase":"PHASE1","title":"Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2010-07","conditions":"Peanut Allergy","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ViaskinTM Peanut"],"phase":"phase_3","status":"active","brandName":"DBV712","genericName":"DBV712","companyName":"DBV Technologies","companyId":"dbv-technologies","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DBV712 is an epicutaneous immunotherapy (EPIT) that delivers allergen to the immune system through the skin to induce immune tolerance. Used for Peanut allergy (oral immunotherapy tolerance induction).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}